Results 1 to 10 of about 1,301 (109)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer [PDF]

Scientific Reports
In recent years there has been a growing interest in metastasis directed radiotherapy (MDRT) in hormone-sensitive oligometastatic prostate cancer. The role of MDRT in castration resistant prostate cancer (CRPC) patients remains controversial.
Marcus Beck, Sebastian Zschaeck, Rana Tahbaz   +2 more
exaly   +3 more sources

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial [PDF]

Frontiers in Oncology
Purpose/objectivePatients with metastatic melanoma on active systemic therapy can develop isolated disease progression while the majority of disease remains controlled (oligoprogression).
Oded Icht, Oded Icht, Oded Icht, Alexander Sun, Alexander Sun, Philip Wong, Philip Wong, Andrew McPartlin, Andrew McPartlin, Thiago Pimentel Muniz, Anna Spreafico, Samuel D. Saibil, J. Nicholas Lukens, Sana D Karam, John De Almeida, Marcus O. Butler, C. Jillian Tsai, C. Jillian Tsai   +17 more
doaj   +2 more sources

Case Report: Serial stereotactic radiotherapy in lieu of systemic therapy change for oligoprogressive breast cancer: eight courses to 17 metastases [PDF]

Frontiers in Oncology
Stereotactic ablative body radiotherapy (SABR) is emerging as a strategy for treating oligoprogressive disease in lieu of changing systemic therapy. We report the case of a patient with oligoprogressive breast cancer who received seven sequential rounds ...
Saad Ashraf, Michelle White, Michelle White, Neda Haghighi, Shankar Siva, Shankar Siva, Keelan Byrne, Michael Liu, Steven David, Steven David   +9 more
doaj   +2 more sources

Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial [PDF]

BMJ Open
Introduction Treatment options remain limited for patients with advanced hepatocellular carcinoma (HCC) who experience oligoprogression during first-line systemic therapy (FLST), especially given the modest efficacy and restricted availability of second ...
Lei Xu, Rui Feng, Haohua Wang, Jinbo Yue, Fang Shi, Kunli Zhu, Shumei Jiang, Xue Dou   +7 more
doaj   +2 more sources

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC [PDF]

Frontiers in Oncology
IntroductionTo assess the efficacy of progression-directed radiation therapy (PDRT) in patients with oligoprogressive non-small cell lung cancer (NSCLC), with particular focus on disease progression and changes in systemic therapy.Materials and ...
Lorenzo De Sanctis, Riccardo Ray Colciago, Giulia Rossano, Matteo Ferrari, Matteo Mombelli, Ilenia Manno, Federica Ferrario, Sara Saufi, Valeria Faccenda, Denis Panizza, Gaia Passarella, Stefania Canova, Diego Luigi Cortinovis, Diego Luigi Cortinovis, Stefano Arcangeli, Stefano Arcangeli   +15 more
doaj   +2 more sources

Consensus statements on the definition, diagnosis, and management of oligoprogressive disease: results of an expert survey of Kazakhstan Cancer Society [PDF]

Exploration of Targeted Anti-tumor Therapy
Aim: Oligoprogressive disease (OPD) has emerged as a clinically relevant and common scenario in oncology, reflecting progression in a limited number of metastatic sites while systemic therapy continues to control the majority of disease.
Dilyara Kaidarova, Indira Omarova, Samat Kaldarbekov, Nazgul Omarbayeva, Maia Dzhugashvili, Elena Ulrikh, Dina Alisheva, Bakhadyr Bereketov, Ilya Tsimafeyeu, Timur Mitin   +9 more
doaj   +2 more sources

Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease [PDF]

OncoImmunology
Stereotactic ablative radiotherapy (SABR) may extend the clinical benefit of immune checkpoint inhibitors (ICI) in patients with oligoprogressive disease. However, individual benefit varies, and validated biomarkers to guide patient selection are lacking.
Juan Zafra-Martin, Juan Luis Onieva, Herminda Jimenez-Rodriguez, Beatriz Martinez, Laura Figueroa-Ortiz, Alicia Roman, Rafael Ordoñez, Elisabeth Pérez-Ruiz, Andres Mesas, Jose Miguel Jurado, Barbara Salas, Elisa Salcedo, Rodolfo Chicas-Sett, Antonio Rueda-Dominguez, Isabel Barragan   +14 more
doaj   +2 more sources

Efficacy and safety of radiotherapy to delay second-line systemic therapy in patients with oligoprogressive hepatocellular carcinoma: study protocol of a multicentre, single-arm, phase II trial [PDF]

Therapeutic Advances in Medical Oncology
Background: Hepatocellular carcinoma (HCC) is a highly aggressive cancer with a paucity of efficacious treatment options, particularly in advanced stages following first-line systemic therapy (FLST).
Haohua Wang, Xiang Zhang, Kunli Zhu, Shumei Jiang, Tianxing Liu, Rui Feng, Xue Dou, Lei Xu, Junyi He, Fang Shi, Jinbo Yue   +10 more
doaj   +2 more sources

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058) [PDF]

Frontiers in Pharmacology
ObjectiveTo investigate the efficacy of anlotinib, an antiangiogenic multikinase inhibitor, as an add-on therapy to first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) for patients with EGFR-mutant non-small cell lung ...
Fei Zhou, Minglei Zhuo, Hongmin Wang, Nong Yang, Jisheng Li, Shi Jin, Zhengxiang Han, Guilin Zeng, Jun Liu, Yang Song, Kangwu Wang, Dabing Huang, Ling Li, Jian Chen, Jinghui Bai, Fengming Ran, Caicun Zhou   +16 more
doaj   +2 more sources

Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study

Discover Oncology
Aims To investigate whether the addition of radiotherapy could be an appropriate option to delay the time-to-next systemic treatment (TTNsT) in patients with oligoprogressive solid tumors who had acquired or innate resistance to immune checkpoint ...
Gianluca Ferini, Stefano Pergolizzi, Mandara Harikar   +2 more
exaly   +2 more sources